Introduction {#sec1-1}
============

Sezary syndrome (SS) is an aggressive erythrodermic leukemic variant of cutaneous T-cell lymphoma in which a significant number of circulating malignant (Sezary) cells are observed in peripheral blood with clonally matching T-cells in the skin.\[[@ref1]\] The disease affects men more often than women and usually occurs in the fifth and sixth decade of life.\[[@ref2][@ref3]\] Patients with SS commonly present with erythroderma, diffuse skin involvement, alopecia, hypertrophic nails, and generalized lymphadenopathy.

There are several accepted treatment approaches for advanced-stage SS, and it includes systemic and skin-directed therapy (SDT; topical corticosteroids, nitrogen mustard, total electron beam irradiation), biological response modifiers (interferon and retinoid), extracorporeal photopheresis (ECP), low-dose methotrexate, and histone deacetylase inhibitors, alone or in combination.\[[@ref4][@ref5]\] We would like to report a case of advanced SS treated successfully with a combination of low-dose methotrexate, SDT, and ECP.

Case Report {#sec1-2}
===========

Medical history {#sec2-1}
---------------

A patient, 50-year-old male, had a history of rash and severe pruritus all over the body for the past 2 years. Initially, the disease presented as skin lesions and the patient was initially diagnosed as sebopsoriasis and treated with methotrexate 20 mg weekly for 8 weeks. However, the patient continued to have itching and spread of lesions with rising total leukocyte counts (TLCs) and no clinical or symptomatic improvement.

The patient consulted hematologist at our institute in light of persistent high TLC. The patient presented with scaly pruritic erythematous lesions involving more than 90% of body surface area. The patient also had hair loss and hypertrophic nails.

Clinical examination and laboratory findings {#sec2-2}
--------------------------------------------

After detailed clinical examination, psoriasis, atopic dermatitis, contact dermatitis, and scabies were ruled out and a provisional diagnosis of SS was made. Peripheral smear revealed TLC was 14900/μl with 55% cells being reported as Sezary cells. It was confirmed by flow cytometry and skin biopsy that was CD3+CD4+ CD7−CD8− on immunohistochemistry \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\]. Absolute CD8+ cell count (586/cu mm) and CD4+/CD8+ ratio (2.09) were within normal range. Serum lactate dehydrogenase was raised at 726 U/L. Contrast-enhanced computerized tomography revealed few insignificant bilateral nodes (\<1.5 cm) in axillary and inguinal region. No visceral involvement was detected. Other routine investigations including liver function tests and kidney function tests were within normal range.

![Atypical lymphoid cells infiltrating dermoepidermal junction as well as epidermis (H and E)](AJTS-13-66-g001){#F1}

![Immunohistochemistry staining showing CD4 positivity](AJTS-13-66-g002){#F2}

Clinical stage and grade of disease {#sec2-3}
-----------------------------------

On the basis of clinical examination and laboratory findings, the disease was graded as T4N0M0B2 (T4 \[\>80% skin involvement\], N0 \[no nodal involvement\], M0 \[no visceral organ involvement\], B2 \[\>1000 Sezary cells/μl in peripheral blood\]). In accordance with joint revision by the International Society for Cutaneous Lymphoma and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, 2007, the disease stage was determined to be IVA1.\[[@ref6]\]

Treatment approach {#sec2-4}
------------------

He received six cycles of CHOP with partial response for not more than 3 months and then started on low-dose methotrexate. With no clinical response to previous treatment (methotrexate; 20 mg/week), and after discussions with the patient, a decision was taken to change methotrexate treatment to low dose (methotrexate; 10 mg/kg) and ECP with adjuvant SDT (calamine lotion and steroid for local application). Empirically, valacyclovir and fluconazole for viral and fungal infection prevention, respectively, were initiated.

Treatment with extracorporeal photopheresis {#sec1-3}
===========================================

A long-term indwelling intravenous catheter (Permacath) was secured for prospective multiple leukocyte harvests. The harvest was performed on COM.TEC (Fresenius Kabi, Germany) with P1YA kit using auto-MNC protocol. About 120--150 ml product volume was targeted in each harvest cycle. For irradiation of collected product, UVA-PIT system with single-use disposable kit (Med Tech Solutions GmbH, Germany) was used. As per the UVA-PIT system operator\'s manual, hematocrit was adjusted to 3%--6% by addition on normal saline, and thereafter, 0.017 ml of 8-methoxypsoralen (8-MOP; methoxsalen; S.A.L.F. S.p.A. Laboratorio Farmacologico, Italy) was added for each ml of diluted product. This system exposes the product to ultraviolet-A (UV-A) irradiation at 2 joules/cm^2^.\[[@ref7]\] Once irradiated, the product was infused back into the patient, immediately, using a standard blood transfusion set. The patient did not have any adverse effects to product transfusion. The patient was instructed to avoid direct sunlight exposure to the skin and eyes. No concurrent blood component transfusion was given to the patient.

One session constitutes leukocyte harvest, adjustment of hematocrit, addition of 8-MOP, exposure to UV-A, and reinfusion back into the patient. Two back-to-back sessions on consecutive days comprised one cycle. Six such cycles were performed fortnightly. After six cycles of ECP, the patient had shown marked clinical improvement (partial remission). Scaly lesions reduced to \<10% BSA; pruritus diminished and affected areas showed hair regrowth remarkably on scalp \[Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}\]. The Sezary cell counts reduced from 55% to 35% on peripheral smear \[[Figure 5](#F5){ref-type="fig"}\].

![Picture of the scalp at the time of initial presentation](AJTS-13-66-g003){#F3}

![Picture of the scalp after six cycles of extracorporeal photopheresis](AJTS-13-66-g004){#F4}

![Percentage of Sezary cells in response to treatment cycles](AJTS-13-66-g005){#F5}

Follow-up {#sec2-5}
---------

Ideally, ECP treatment should be continued for 6 months according to the published guidelines before tapering to one cycle every 6--12 months.\[[@ref8][@ref9][@ref10]\] However, due to financial constraints, the patient was unable to continue beyond six cycles. To maintain the attained response, he was counseled and continued on steroids (for local application) with addition of oral gemcitabine (1000 mg/m^2^) on day 1, 8, and 15 in a 28-day cycle. The patient completed six such cycles of gemcitabine. The patient continues to be in partial remission at last follow-up 6 months after discharge.

Case Discussion {#sec1-4}
===============

Clinicians differ in their preferred treatment approach as there is no standard initial therapy and paucity of controlled clinical trial data to direct the selection of treatment modality. There are several accepted treatment approaches for advanced-stage SS. This was possibly the first SS patient, in India, treated with ECP in conjunction with low-dose methotrexate and SDT. Authors approach to therapy was consistent with consensus recommendations regarding the treatment of SS that has been proposed by almost all professional bodies including the United States Cutaneous Lymphoma Consortium and the National Comprehensive Cancer Network.\[[@ref4][@ref8]\] ECP either as monotherapy or in combination with other therapies offers good treatment alternative and the possibility of prolonged survival. Further studies focusing on ECP treatment in combination with other therapies in SS patients are needed.
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